Transitioning from preclinical to Phase I/II clinical trials is biopharma’s highest-risk inflection point. Learn the regulatory and vendor selection strategies that protect your asset
13 Jul 2026
Transitioning from 100% Source Data Verification to Risk-Based Quality Management (RBQM) is a regulatory mandate and a financial imperative. Discover how biopharma sponsors are implementing RBQM in 2026
13 Jul 2026
Clinical trial delays cost biopharma millions in direct expenses and lost commercial revenue. Learn how strategic Business Development (BD) prevents these catastrophic bottlenecks.
13 Jul 2026